The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin trial
Initiatives
-
JUPITER is a completed, randomized, double-blind, placebo-controlled trial of rosuvastatin 20 mg daily in the prevention of cardiovascular disease.
- Start Year
- 2012
- End Year
- 2015
- Funding
- AstraZeneca
Visit JUPITER
| Investigators | Contacts |
|---|---|
|
Design
- Study design
- Clinical trial cohort
- Follow Up
- A median of 1.9 years follow up
Marker Paper
Recruitment
- Sources of Recruitment
-
- Individuals
Number of participants
- Number of participants
- 17,802
- Number of participants with biosamples
- Supplementary Information
- Men who were at least 50 years old and women at least 60 years old were eligible for the trial (no history of cardiovascular disease)
Access
Availability of data and biosamples
| Data | |
| Biosamples | |
| Other |